ticker
stringlengths 2
5
| disease
stringlengths 3
196
| stage
stringclasses 15
values | date
stringlengths 19
19
| catalyst
stringlengths 18
760
| label
int64 -1
1
|
|---|---|---|---|---|---|
BMY
|
Urothelial Carcinoma
|
Approved
|
2021-08-20 00:00:00
|
FDA approval announced August 20, 2021.
| 1 |
HCM
|
Primary immune thrombocytopenia (ITP)
|
Phase 3
|
2023-08-21 00:00:00
|
Phase 3 trial met is primary endpoint, noted August 21, 2023.
| 0 |
MRK
|
Measles, Mumps, and Rubella Virus Vaccine Live
|
Approved
|
2023-03-06 00:00:00
|
Approved March 6, 2023.
| 1 |
AGIO
|
Advanced hematologic malignancies with an IDH2 mutation
|
Approved
|
2017-08-01 00:00:00
|
Approval announced August 1, 2017.
| 1 |
LLY
|
Alzheimer’s disease
|
Phase 3
|
2023-07-17 00:00:00
|
Phase 3 data presented at AAIC reported a 60% slowing of decline compared to placebo with nearly half of participants at earlier stage of disease on donanemab had no clinical progression at 1 year, noted July 17, 2023.
| 1 |
GILD
|
Adult patients with r/r ALL - cancer
|
Approved
|
2021-10-01 00:00:00
|
Approved October 1, 2021.
| 1 |
MRTX
|
Urothelial Carcinoma (Bladder)
|
Phase 2
|
2020-09-18 00:00:00
|
Phase 2 at ESMO September 2020 noted objective response rate of 37% (1 complete response and 10 partial responses)
| 0 |
ABBV
|
Crohn's disease (induction/maintenance)
|
Approved
|
2023-05-18 00:00:00
|
Approved May 18, 2023.
| 1 |
BIIB
|
Mitochondrial myopathies (MM)
|
Phase 2
|
2018-03-01 00:00:00
|
Phase 2 initial data released March 1, 2018 - endpoints not met.
| 0 |
RHHBY
|
Acute Myeloid Leukemia (AML)
|
Approved
|
2020-10-16 00:00:00
|
FDA approval announced October 16, 2020.
| 1 |
IVA
|
Nonalcoholic fatty liver disease (NAFLD)
|
Phase 2
|
2023-06-13 00:00:00
|
Phase 2 data of 800mg achieved the primary efficacy endpoint demonstrating a 44% reduction of hepatic fat measured by proton magnetic resonance spectroscopy (1H-MRS) following 24 weeks of treatment in patients with nonalcoholic fatty liver disease (NAFLD), noted June 13, 2023.
| 1 |
MTEM
|
Multiple Myeloma
|
Phase 1
|
2023-04-07 00:00:00
|
Partial clinical hold placed April 7, 2023.
| 0 |
CYAD
|
Multiple Myeloma
|
Phase 1
|
2022-12-21 00:00:00
|
Phase 1 additional data reported 5 partial responses, program has been discontinued, noted December 21, 2022.
| -1 |
RHHBY
|
Paroxysmal nocturnal hemoglobinuria (PNH)
|
BLA Filing
|
2023-09-06 00:00:00
|
BLA accepted by FDA, noted Septemeber 6, 2023
| 0 |
GILD
|
Hepatitis C
|
Approved
|
2020-03-19 00:00:00
|
sNDA FDA Approval announced March 19, 2020.
| 1 |
GLSI
|
Breast cancer
|
Phase 2b
|
2022-05-26 00:00:00
|
Phase 2b abstract reported a DFS rate of 100% versus 89.4%, and just under 23% of subjects experienced an immune response to GP2 by DTH at baseline, noted May 26, 2022.
| 0 |
REGN
|
Chronic obstructive pulmonary disease (COPD)
|
Phase 3
|
2023-03-23 00:00:00
|
Phase 3 demonstrated clinically meaningful and highly significant reduction (30%) in moderate or severe acute exacerbations of COPD over 52 weeks, while also demonstrating significant improvements in lung function, quality of life and COPD respiratory symptoms, noted March 23, 2023. Data expected in 2025.
| 1 |
ABBV
|
Waldenström’s Macroglobulinemia
|
Approved
|
2015-01-29 00:00:00
|
Approved January 29, 2015 - PCYC
| 1 |
SUPN
|
ADHD
|
Approved
|
2021-04-02 00:00:00
|
FDA approval announced April 2, 2021.
| 1 |
VYNE
|
Papulopustular rosacea
|
Approved
|
2020-05-29 00:00:00
|
FDA Approval announced May 29, 2020.
| 1 |
BPMC
|
EGFR exon 20 insertion-positive NSCLC
|
Phase 1/2
|
2023-06-05 00:00:00
|
Phase 1/2 initial clinical data presented at ASCO reported a partial CNS response and a CNS complete response, noted June 5, 2023.
| 1 |
BGNE
|
Gastric or gastroesophageal junction (G/GEJ) adenocarcinoma
|
Phase 3
|
2023-10-21 00:00:00
|
Phase 3 data presented at ESMO reported that OS in the TIS arm was significantly improved compared with the PBO arm in the ITT population (median OS: 15.0 mo vs 12.9 mo, respectively; HR=0.80 [95% CI: 0.70, 0.92]; 1-sided P=0.0011), noted October 21, 2023.
| 1 |
CLNN
|
Amyotrophic Lateral Sclerosis (ALS)
|
Phase 2/3
|
2023-09-25 00:00:00
|
Phase 2/3 post hoc results showed significantly improved survival with a 49% decreased risk of death for the covariate risk-adjusted analyses compared to the largest U.S. clinical database of previous amyotrophic lateral sclerosis (ALS) trials (PRO-ACT), noted September 25, 2023.
| 1 |
VTRS
|
Trastuzumab biosimilar
|
Approved
|
2017-12-01 00:00:00
|
Approval announced December 1, 2017.
| 1 |
IDYA
|
Metastatic uveal melanoma (MUM)
|
Phase 2
|
2023-04-23 00:00:00
|
Phase 2 darovasertib and crizotinib combination data reported a cORR of 45%, DCR of 90% and median PFS of ~7 months in 20 evaluable First-Line MUM patients, noted April 23, 2023.
| 1 |
TTNP
|
Parkinson's disease
|
Phase 1/2
|
2018-07-02 00:00:00
|
DSMB recommended trial to continue - July 2, 2018 but further enrollment has been postponed due to lack of resources.
| 0 |
ACRX
|
Moderate-to-severe acute pain following a surgical procedure
|
Approved
|
2018-11-02 00:00:00
|
FDA Approval announced November 2, 2018.
| 1 |
CHRS
|
Cancer
|
CRL
|
2023-09-25 00:00:00
|
CRL issued September 25, 2023.
| 0 |
OKYO
|
Dry Eye Disease
|
Phase 2
|
2023-10-05 00:00:00
|
Phase 2 data reported a dropout rate at 5.4% and that treatment was well tolerated, noted October 5, 2023.
| 1 |
MRK
|
Ebola
|
Approved
|
2023-08-03 00:00:00
|
Approval in children aged 12 months and older on August 3, 2023.
| 1 |
ADAG
|
Solid tumors
|
Phase 1/2
|
2023-04-18 00:00:00
|
Phase 1/2 trial data presented at AACR demonstrated that combination was well-tolerated up to 10 mg/kg Q3W or Q6W and with repeat dosing beyond 4 cycles, noted April 18, 2023.
| 1 |
LLY
|
Atopic dermatitis
|
PDUFA
|
2021-07-16 00:00:00
|
Noted FDA will not meet assigned July 2021 PDUFA date - July 16, 2021
| 1 |
FGEN
|
Idiopathic pulmonary fibrosis
|
Phase 3
|
2023-06-26 00:00:00
|
Phase 3 study did not meet primary endpoints, noted June 26, 2023.
| 1 |
JNJ
|
COVID-19 vaccine - two-dose regimen
|
Approved
|
2021-10-20 00:00:00
|
EUA for second dose for adults aged 18 and older at least two months following primary vaccination with single-shot Johnson & Johnson COVID-19 vaccine; and for eligible individuals who received a different authorized or approved COVID-19 vaccine, noted October 20, 2021.
| 1 |
ARDS
|
Ventilator associated pneumonia (VAP) / Staphylococcus aureus
|
Phase 3
|
2023-06-20 00:00:00
|
FDA granted Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD), noted June 20, 2023. The official determination regarding using the LPAD pathway will be made after the Company's request following the filing of the biologics license application (BLA).
| -1 |
FUSN
|
Solid tumors
|
Phase 1
|
2023-06-26 00:00:00
|
Phase 1 multi-dose safety and imaging data presented at SNMMI with Cold/Hot dosing regimen demonstrated potential to improve therapeutic index and safety profile, noted June 26, 2023.
| 1 |
NVS
|
Rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, and plaque psoriasis
|
Approved
|
2023-03-21 00:00:00
|
Approved March 21, 2023.
| 1 |
IMMP
|
Non-small cell lung cancer; Head and neck cancer
|
Phase 2
|
2023-11-03 00:00:00
|
Additional biomarker results shared at SITC showed statistically significant increases of Th1 biomarkers (IFN-gamma, CXCL-10), circulating immune cells (lymphocytes), and RNA levels of immune activating genes were observed and linked to improved clinical outcomes, noted November 3, 2023.
| 1 |
RARE
|
GNE Myopathy
|
Phase 3
|
2017-08-22 00:00:00
|
Phase 3 data released August 22, 2017 - endpoints not met.
| 0 |
PRTA
|
Parkinson's disease
|
Phase 2
|
2022-03-16 00:00:00
|
Phase 2 results presented showed that participants with PD who were treated for two years (early-start group) showed slower decline of Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part 3 scores relative to participants treated with for one year (delayed-start group), noted March 16, 2022.
| 1 |
MOLN
|
Acute myeloid leukemia (AML)
|
Phase 1
|
2023-11-02 00:00:00
|
Phase 1 data from ASH abstract reported that one of the two patients evaluable for MP0533 antitumor activity in the third treatment cohort achieved a response, noted November 2, 2023.
| 1 |
AERI
|
Glaucoma
|
Approved
|
2019-03-13 00:00:00
|
FDA Approval announced March 12, 2019.
| 1 |
ZYME
|
3L+ HER2-positive, HR-positive breast cancer
|
Phase 2
|
2022-12-09 00:00:00
|
Phase 2 data reported a confirmed objective response rate (cORR) of 33%, disease control rate (DCR) of 92%, and median progression-free survival (mPFS) of 9.6 months, noted December 9, 2022.
| 0 |
MGTX
|
Xerostomia
|
Phase 1
|
2023-10-24 00:00:00
|
Phase 1 OLE data presented at ESGCT showed that dosing was safe and well-tolerated at all dose levels, with no treatment-related serious adverse events or dose limiting toxicity, noted October 24, 2023.
| 1 |
INBX
|
Chondrosarcoma and mesothelioma
|
Phase 1
|
2023-04-26 00:00:00
|
Clinical hold lifted, noted April 26, 2023. Phase 1 combination cohorts are expected to begin reading out by year end 2023 and data from the registration-enabling trial in unresectable or metastatic conventional chondrosarcoma is expected during the 2H 2024.
| 0 |
AGEN
|
Solid tumors, melanoma
|
Phase 1
|
2023-06-03 00:00:00
|
Phase 1 data at ASCO reported an overall response rate (ORR) was 11% (n=2); 37% had SD (n=7) resulting in a disease control rate (DCR) (CR, PR or SD) of 47%, noted June 3, 2023.
| 0 |
FGEN
|
Anaemia in Chronic Kidney Disease
|
CRL
|
2021-08-11 00:00:00
|
CRL announced August 11, 2021.
| 0 |
AVXL
|
Mild to moderate Alzheimer’s disease
|
Phase 2/3
|
2023-09-14 00:00:00
|
Phase 2b/3 full data reported that the least-squares mean (LSM) change from baseline to 48 weeks between the blarcamesine and placebo groups were −1.783; for ADAS-Cog13, and −0.456 for CDR-SB in patients with early Alzheimer's disease, noted September 14, 2023.
| 0 |
PFE
|
Early stage breast cancer
|
Phase 3
|
2020-05-29 00:00:00
|
Phase 3 trial unlikely to show a statistically significant improvement in the primary endpoint following futility analysis - May 29, 2020.
| 1 |
PBYI
|
Metastatic triple negative breast cancer with a HER2 mutation
|
Phase 2
|
2022-10-27 00:00:00
|
Phase 2 basket trial interim efficacy results showed that the objective response rate (ORR) was 35% overall, 30% in patients pretreated with TKIs, and 50% in patients not pretreated with TKIs. Response or stable disease lasting for ≥ 48 weeks was observed in 7 patients (6 PR, 1 SD), noted October 27, 2022.
| 1 |
TCDA
|
Chronic kidney disease
|
CRL
|
2020-08-24 00:00:00
|
CRL announced August 24, 2020.
| 0 |
MRK
|
Metastatic castration-resistant prostate cancer (mCRPC)
|
Phase 3
|
2022-08-03 00:00:00
|
Phase 3 trial results were not statistically significant, noted August 3, 2022.
| 0 |
NVAX
|
COVID-19, COVID-19 vaccine, Influenza
|
Phase 2
|
2023-05-09 00:00:00
|
Phase 2 data reported that the highest dose stand-alone COVID vaccine candidate achieved statistically significant anti-S IgG and neutralization responses approximately 30% higher than Novavax's prototype COVID vaccine while maintaining comparable safety, noted May 9, 2023
| 1 |
MNOV
|
Idiopathic pulmonary fibrosis (IPF)
|
Phase 2
|
2021-08-12 00:00:00
|
Phase 2 data released August 12, 2021 - no clinically meaningful trends.
| 0 |
AMGN
|
Hematopoietic Syndrome of Acute Radiation Syndrome
|
Approved
|
2021-02-02 00:00:00
|
FDA approval announced in earnings release - February 2, 2021.
| 1 |
ATRA
|
Multiple sclerosis
|
Phase 2
|
2022-10-26 00:00:00
|
Phase 2 OLE data reported that all with stable EDSS remaining in the OLE continued to have a stable EDSS for a median of 41.2 months, noted October 26, 2022.
| 0 |
SVRA
|
MRSA in cystic fibrosis
|
Phase 3
|
2020-12-10 00:00:00
|
Phase 3 trial missed primary endpoint - December 10, 2020. Development to be stopped.
| -1 |
ADMP
|
Anaphylaxis
|
Approved
|
2018-09-27 00:00:00
|
FDA Approval announced September 27, 2018.
| 1 |
NVO
|
Hemophilia A
|
Approved
|
2019-02-19 00:00:00
|
FDA Approval announced February 19, 2019.
| 1 |
TBPH
|
Acute Lung Injury (ALI) caused by COVID-19
|
Phase 2
|
2021-06-21 00:00:00
|
Phase 2 trial did not meet primary endpoint - June 21, 2021.
| 1 |
BLRX
|
Pancreatic ductal adenocarcinoma (PDAC)
|
Phase 2
|
2023-07-17 00:00:00
|
Phase 2b trial initiated, noted July 17, 2023.
| 0 |
MNKKQ
|
Hepatorenal syndrome (HRS) Type 1
|
CRL
|
2022-02-22 00:00:00
|
CRL reissued February 22, 2022.
| 0 |
ZYME
|
Solid Tumors
|
Phase 1
|
2023-04-18 00:00:00
|
Additional data reported that anti-tumor activity was observed in breast cancer and gastric cancer PDXs representing a range of HER2 expression, noted April 18, 2023.
| 1 |
BIIB
|
Alzheimer’s disease
|
Approved
|
2021-06-07 00:00:00
|
FDA approval announced June 7, 2021.
| 1 |
ADAG
|
Solid tumors
|
Phase 1/2
|
2023-04-18 00:00:00
|
Dose escalation data presented at AACR showed a compelling safety profile for ADG126, with no Grade 3 or higher TRAEs reported at repeat doses up to 20 mg/kg. Across all dose levels, the disease control rate was 37% among 27 evaluable patients, noted April 18, 2023.
| 1 |
GMAB
|
Multiple myeloma
|
Approved
|
2020-05-01 00:00:00
|
FDA Approval announced May 1, 2020.
| 1 |
NBRV
|
Cystic fibrosis (CF)
|
Phase 1
|
2022-11-28 00:00:00
|
Phase 1 top-line data reported that treatment was well-tolerated, noted November 28, 2022.
| 1 |
TERN
|
Nonalcoholic steatohepatitis (NASH)
|
Phase 2a
|
2023-08-08 00:00:00
|
Phase 2a topline data reported that the trial met all primary and secondary endpoints, noted August 8, 2023.
| 0 |
AVXL
|
Rett syndrome
|
Phase 2
|
2023-06-28 00:00:00
|
Phase 2 long-term clinical study results demonstrated disease modifying effect of ANAVEX2-73 (blarcamesine) for adult patients with Rett syndrome, noted June 28, 2023.
| 1 |
RVNC
|
Cervical dystonia
|
Phase 3
|
2021-11-09 00:00:00
|
Open label data reported a median duration of effect ranging from 19.9 weeks to 26.0 weeks across doses. The most common treatment-related adverse events were muscular weakness (4.9%), dysphagia (4.2%) and injection site pain (2.7%), noted November 9, 2021.
| 1 |
KPRX
|
Persistent epithelial defects
|
Phase 1
|
2023-04-26 00:00:00
|
Phase 1 interim results reported that 62.5% of patients achieved the primary endpoint of healing over the 4-week period , noted April 26, 2023.
| 1 |
NVS
|
HR + Metastatic breast cancer (MBC)
|
Phase 3
|
2018-08-23 00:00:00
|
Phase 3 trial met primary endpoint - August 23, 2018 with data to be presented at an upcoming medical congress.
| 1 |
BMY
|
Urothelial carcinoma, Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancers
|
Phase 1/2
|
2019-11-09 00:00:00
|
Phase 1/2 updated data at SITC November 9, 2019 noted ORR was 53% (20/38) with 34% (13/38) complete response (CR) rate.
| 0 |
BMY
|
First-line, lower-risk Myelodysplastic syndromes (MDS)
|
Approved
|
2023-08-28 00:00:00
|
Approved August 28, 2023.
| 1 |
ACER
|
induced Vasomotor Symptoms (iVMS) associated with menopause
|
Phase 1
|
2023-03-17 00:00:00
|
Phase 2a PoC did not meet its primary endpoint of ability to decrease the frequency or severity of hot flashes in postmenopausal women. As a result, the company is pausing the program until a full dataset review, noted March 17, 2023
| 1 |
VCNX
|
Huntington’s disease
|
Phase 2
|
2022-06-10 00:00:00
|
Phase 2 data reported that treatment restores the ability to benefit from experience, noted June 10, 2022.
| 1 |
EIGR
|
Hepatitis Delta Virus (HDV) infection
|
Phase 3
|
2023-09-12 00:00:00
|
Phase 3 LIMT-2 trial discontinued due to DSMB recommendation, noted September 12, 2023.
| -1 |
NRSN
|
Parkinson's disease
|
Phase 1
|
2023-05-02 00:00:00
|
Biomarker data reported statistically significant decreased levels of novel biomarker AGO2 observed in newly diagnosed people living with Parkinson's disease (PD) compared to healthy individuals, noted May 2, 2023.
| 1 |
BNTX
|
Cancer, PD-(L)1-resistant non-small cell lung cancer
|
Phase 1/2
|
2023-06-02 00:00:00
|
Phase 1/2 data reported that the ORR was 29.6% and DCR was 70.4%, including one complete response, 7 partial responses and 11 patients with stable disease, noted June 2, 2023.
| 0 |
AADI
|
PEComa
|
Approved
|
2021-11-23 00:00:00
|
Approved November 23, 2021.
| 1 |
CRSP
|
CD19+ B-cell malignancies
|
Phase 1
|
2021-10-12 00:00:00
|
Phase 1 data demonstrated 58% overall response rate (ORR) and 38% complete response (CR) rate with a single dose at Dose Level 2 (DL2) and above on an intent-to-treat (ITT) basis. Durable responses achieved with six-month CR rate of 21% and longest response on-going at over 18 months after initial infusion, noted October 12, 2021.
| 1 |
SRPT
|
Duchenne muscular dystrophy (DMD)
|
Phase 1b
|
2021-10-11 00:00:00
|
Phase 1b open label interim results from the first 11 participants in Cohort 1 (ambulatory boys aged 4-7 years) provided evidence of robust expression of micro-dystrophin and no new safety signals were identified, September 24, 2021. Functional results from study cohort 1 (n=11, ages 4-7) found participants improved 3.0 points on NSAA six months after treatment - noted October 11, 2021.
| 1 |
RHHBY
|
Chronic Lymphocytic Leukemia
|
Approved
|
2019-05-15 00:00:00
|
FDA approval announced May 15, 2019.
| 1 |
ALDX
|
Dry eye disease
|
Phase 3
|
2022-07-12 00:00:00
|
Phase 3 crossover results reported that met both primary endpoints, noted July 12, 2022.
| 0 |
CVAC
|
Solid tumors
|
Phase 1
|
2022-11-11 00:00:00
|
Phase 1 data reported that five out of 30 patients (17%) experienced a partial response and no objective responses were observed in the 10 patients of the single-agent cohort, noted November 11, 2022.
| 1 |
KROS
|
Iron deficiency anemia
|
Phase 2
|
2022-12-12 00:00:00
|
Phase 2 preliminary data reported that KER-047 was generally well tolerated by this patient, with no serious adverse events or dose-limiting toxicities, noted December 12, 2022.
| 1 |
OBSV
|
Endometriosis
|
Phase 3
|
2021-01-10 00:00:00
|
Phase 3 trial discontinued due to enrollment challenges.
| -1 |
HOTH
|
Aggressive systemic mastocytosis (ASM), mast cell leukemia (MCL), and systemic mastocytosis with associated hematological neoplasm (SM-AHN).
|
Phase 1a
|
2023-09-13 00:00:00
|
Preclinical Results of Novel HT-KIT Therapeutic Performed at NC State University demonstrated that gastrointestinal Stromal Tumors Cells Rapidly Died Between 48 and 72 Hours After Exposure to HT-KIT. HT-KIT Shows Positive Results in AML, noted September 13, 2023.
| 1 |
STTK
|
Ovarian Cancer
|
Phase 1a
|
2023-06-05 00:00:00
|
Phase 1a monotherapy data shared at ASCO reported that the best response was stable disease in 6/27 response evaluable (22%) pts, noted June 5, 2023.
| 1 |
LLY
|
Axial Spondyloarthritis
|
Approved
|
2019-08-26 00:00:00
|
FDA Approval announced August 26, 2019.
| 1 |
IONS
|
Hypertriglyceridemia
|
Phase 3
|
2021-11-13 00:00:00
|
Phase 3 data reported a significant reduction in total TRL particle (TRLP) concentration by 51%. Total LDL particle (LDLP) concentration was not changed, small LDLP numerically decreased by 39% while medium LDLP increased by 187%, noted November 13, 2021.
| 1 |
GOVX
|
Head and neck squamous cell carcinoma (HNSCC)
|
Phase 1/2
|
2023-07-10 00:00:00
|
Phase 1/2 study data presented at AHNS resulted on impairment of tumor growth (i.e., "stable disease" using RECIST 1.1 evaluation criteria) in targeted lesions was seen in 5 of 7 patients; tumor response assessment in one patient remains under study, noted July 10, 2023.
| 1 |
LEGN
|
Molluscum Contagiosum
|
Phase 3
|
2021-09-23 00:00:00
|
Phase 3 safety data showed TEAEs reported in greater than 5% of subjects in the SB206 treated groups were all at the application site (pain, erythema, pruritis, exfoliation, and dermatitis) with the high majority of these TEAEs being mild or moderate by severity, noted September 23, 2021.
| 1 |
CYTK
|
Hypertrophic cardiomyopathy (HCM)
|
Phase 2
|
2023-05-22 00:00:00
|
Cohort 4 data reported that overall, 58% of patients experienced a clinical reduction in symptom burden: 12.5% had a small improvement (≥ 5-10 points), 20% had a moderate to large improvement (≥ 10-20 points), and 25% had a large to very large improvement, noted May 22, 2023.
| 1 |
VECT
|
Short bowel syndrome - colon-in-continuity
|
Phase 2
|
2023-10-16 00:00:00
|
Additional Phase 2 data reported that 33% of the patients achieving clinical response and PS volume reduction reached a statistically significant 40% at week 24 and the effect was maintained with a 52% volume reduction at week 52, noted October 16, 2023.
| 1 |
EXEL
|
First-line BRAF wild-type metastatic or unresectable locally advanced melanoma
|
Phase 3
|
2019-06-20 00:00:00
|
Phase 3 data did not meet primary endpoint - June 20, 2019.
| 1 |
EGRX
|
Supraventricular tachycardia (SVT) - atrial fibrillation and atrial flutter
|
CRL
|
2023-05-31 00:00:00
|
CRL received on May 31, 2023.
| 0 |
ABCL
|
COVID-19 Anti-body
|
Approved
|
2021-12-03 00:00:00
|
Emergency Use Authorization (EUA) expanded for children under 12 years old, noted December 3, 2021.
| 0 |
INCY
|
Myelfibrosis
|
Phase 2
|
2022-12-12 00:00:00
|
Phase 2 data reported that 28.1% (9), 3.1% (1) and 0% of patients who received daily followed by weekly dosing experienced ≥10%, ≥25% and ≥35% reduction in spleen volume, respectively, noted December 12, 2022,
| 1 |
EPIX
|
Metastatic castration-resistant prostate cancer (mCRPC)
|
Phase 1
|
2023-10-22 00:00:00
|
Phase 1 updated data presented at ESMO reported a PSA50 of 88%, PSA90 of 69%, and PSA <0.2 ng/mL of 56%, noted October 22, 2023.
| 1 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.